450 related articles for article (PubMed ID: 35700142)
1. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Green JB; Mottl AK; Bakris G; Heerspink HJL; Mann JFE; McGill JB; Nangaku M; Rossing P; Scott C; Gay A; Agarwal R
Nephrol Dial Transplant; 2023 Mar; 38(4):894-903. PubMed ID: 35700142
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
[TBL] [Abstract][Full Text] [Related]
3. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
[TBL] [Abstract][Full Text] [Related]
4. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R; Tu W; Farjat AE; Farag YMK; Toto R; Kaul S; Lawatscheck R; Rohwedder K; Ruilope LM; Rossing P; Pitt B; Filippatos G; Anker SD; Bakris GL;
Ann Intern Med; 2023 Dec; 176(12):1606-1616. PubMed ID: 38048573
[TBL] [Abstract][Full Text] [Related]
5. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
6. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
[TBL] [Abstract][Full Text] [Related]
7. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
Zheng Y; Ma S; Huang Q; Fang Y; Tan H; Chen Y; Li C
Kidney Blood Press Res; 2022; 47(4):219-228. PubMed ID: 35034019
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
Vizcaya D; Kovesdy CP; Reyes A; Pessina E; Pujol P; James G; Oberprieler NG
J Comp Eff Res; 2023 Aug; 12(8):e230076. PubMed ID: 37387399
[No Abstract] [Full Text] [Related]
11. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.
Goulooze SC; Heerspink HJL; van Noort M; Snelder N; Brinker M; Lippert J; Eissing T
Clin Pharmacokinet; 2022 Jul; 61(7):1013-1025. PubMed ID: 35508594
[TBL] [Abstract][Full Text] [Related]
12. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Heerspink HJL; Birkenfeld AL; Cherney DZI; Colhoun HM; Ji L; Mathieu C; Groop PH; Pratley RE; Rosas SE; Rossing P; Skyler JS; Tuttle KR; Lawatscheck R; Scott C; Edfors R; Scheerer MF; Kolkhof P; McGill JB
Diabetes Res Clin Pract; 2023 Oct; 204():110908. PubMed ID: 37805000
[TBL] [Abstract][Full Text] [Related]
15. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
16. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
18. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T; Goulooze SC; van den Berg P; van Noort M; Ruppert M; Snelder N; Garmann D; Lippert J; Heinig R; Brinker M; Heerspink HJL
Diabetes Obes Metab; 2024 Mar; 26(3):924-936. PubMed ID: 38037539
[TBL] [Abstract][Full Text] [Related]
20. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
